Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

677
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
677
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

518
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
518
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

608
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
608
Glial Cells01:04

Glial Cells

88.0K
Overview
88.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of preservative-free versus preserved timolol eye drops in glaucoma: A randomized crossover study.

Journal of the Chinese Medical Association : JCMA·2026
Same author

Prostaglandin EP2 Receptor and Cystoid Macular Edema in Phakic Posttrabeculectomy Eyes.

JAMA ophthalmology·2025
Same author

Optical coherence tomography-guided early postoperative management of XEN Gel implant.

Taiwan journal of ophthalmology·2023
Same author

Anti-apoptotic and autophagic effect: Using conditioned medium from human bone marrow mesenchymal stem cells to treat human trabecular meshwork cells.

Regenerative therapy·2023
Same author

Bleb-related infection after primary trabeculectomy: medical chart reviews from 1993 to 2021.

The British journal of ophthalmology·2022
Same author

Widen the Applicability of a Convolutional Neural-Network-Assisted Glaucoma Detection Algorithm of Limited Training Images across Different Datasets.

Biomedicines·2022

Related Experiment Video

Updated: Aug 15, 2025

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.2K

Neuroprotection in Glaucoma: Basic Aspects and Clinical Relevance.

Che-Yuan Kuo1, Catherine Jui-Ling Liu1,2

  • 1Department of Ophthalmology, Taipei Veterans General Hospital, Taipei 11217, Taiwan.

Journal of Personalized Medicine
|December 29, 2022
PubMed
Summary

Glaucoma treatment faces challenges as lowering intraocular pressure (IOP) is not always effective. This review explores neuroprotection strategies for retinal ganglion cells (RGCs) to improve glaucoma therapy beyond IOP control.

Keywords:
glaucomatous optic neuropathyglutamateoptic nerve protection

More Related Videos

An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina
09:46

An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina

Published on: July 15, 2025

440
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.5K

Related Experiment Videos

Last Updated: Aug 15, 2025

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.2K
An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina
09:46

An Ex Vivo Explant Model for Studying Glial Interactions in the Mouse Retina

Published on: July 15, 2025

440
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.5K

Area of Science:

  • Ophthalmology
  • Neuroscience
  • Pharmacology

Background:

  • Glaucoma is a neurodegenerative disease primarily impacting retinal ganglion cells (RGCs).
  • Elevated intraocular pressure (IOP) is a key risk factor, but current treatments focused solely on IOP reduction are often insufficient.
  • Understanding the biomolecular mechanisms of RGC degeneration is crucial for developing novel therapeutic strategies.

Purpose of the Study:

  • To review clinically relevant, IOP-independent neuroprotection strategies for glaucoma.
  • To summarize preclinical and clinical data on recent advances in neuroprotection research.
  • To discuss the feasibility and challenges of translating neuroprotection therapies into clinical practice.

Main Methods:

  • Literature review of preclinical and clinical studies on glaucoma neuroprotection.
  • Analysis of therapeutic approaches targeting RGC survival and function.
  • Examination of pathogenic mechanisms, including glutamate excitotoxicity.

Main Results:

  • Numerous neuroprotection modalities show promise in animal models, but clinical translation remains a significant hurdle.
  • Several therapeutic agents and approaches are being investigated for their potential to protect RGCs independently of IOP.
  • Understanding mechanisms like glutamate excitotoxicity is key to developing effective neuroprotective treatments.

Conclusions:

  • IOP-independent neuroprotection offers a promising avenue for glaucoma treatment beyond current standards of care.
  • Further research and clinical trials are necessary to overcome challenges in translating neuroprotection strategies into effective therapies.
  • Targeting RGC survival pathways, including those related to glutamate excitotoxicity, is essential for future glaucoma management.